Ticagrelor Tablet
Product Images NDC 11788-157

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 11788-157). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aiping Pharmaceutical, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

60 mg (60s)

60 mg (60s)
Each tablet of DG 11788-157-80 contains 60 mg of ticagrelor. It is an adult dosage medication that should be stored at 25°C with excursions permitted to 15-30°C. It is important to keep this medication out of reach of children. The medication guide and instructions for dispensing can be found at aipingpharmaceutical.com. Manufactured by AiPing Pharmaceutical, Inc. located in Hauppauge, NY.*
FDA Label Image

90 mg (100s)

90 mg (100s)
This is a description of Ticagrelor Tablets 90 mg containing 100 tablets. Each tablet contains 90 mg of ticagrelor and the usual adult dosage can be found in the package insert. It is advised to keep the medication out of the reach of children and store it at 25°C (77°F) with excursions permitted to 15-30°C (59-86°F). The medication guide is available at the website provided. The tablets are manufactured for AiPing Pharmaceutical, Inc. in Hauppauge, NY.*
FDA Label Image

90 mg (60s)

90 mg (60s)
The text provides information about Ticagrelor Tablets in 90 mg strength. It advises dispensing the Medication Guide to each patient. The tablets contain 90 mg of ticagrelor and the usual adult dosage information can be found in the package insert. A warning is given to keep the medication out of reach of children. It should be stored at 25°C (77°F) or 15-30°C (59-86°F) as per USP Controlled Room Temperature guidelines. The Medication Guide can be accessed online. The product is manufactured for AiPing Pharmaceutical, Inc. located in Hauppauge, NY. The revision date of the information is 03/2026.*
FDA Label Image

Chemical Structure (Chemical Structure)

Chemical Structure (Chemical Structure)
FDA Label Image

Figure 15 (Figure 15)

Figure 15 (Figure 15)
FDA Label Image

Figure 16 (Figure 16)

Figure 16 (Figure 16)
This is a tabular data showing subgroup analyses of ticagrelor in the THEMIS study. It includes information on different characteristics such as age, sex, race, geographic region, aspirin dose, HbA1c at baseline, Insulin use, history of angina, multivessel coronary artery disease, history of PCI, and more. The analysis presents Hazard Ratios (HR) and 95% Confidence Intervals for various subgroups based on the mentioned characteristics. This data can be used to understand the impact and effectiveness of ticagrelor in different patient groups.*
FDA Label Image

Figure 17 (Figure 17)

Figure 17 (Figure 17)
This is a comparison of the time to the first occurrence of stroke or death in a study titled "THALES". The results show the percentage of events occurring in patients who received Ticagrelor 90 mg (5.4%) compared to those who received a placebo (6.5%).*
FDA Label Image

Figure 18 (Figure 18)

Figure 18 (Figure 18)
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
This text mentions the results of a study comparing the mean inhibition of platelet aggregation following single oral doses of placebo, 180 mg ticagrelor, or 600 mg clopidogrel. It indicates the specific doses used and the comparison between the three groups regarding their effects on platelet aggregation.*
FDA Label Image

Figure 6 (Figure 6)

Figure 6 (Figure 6)
This is a description of a study comparing the mean inhibition of platelet aggregation (IPA) between different medications over a period of 6 weeks. The medications being evaluated are ticagrelor at a dose of 90 mg twice daily, clopidogrel at a dose of 75 mg daily, and a placebo. Platelet aggregation was induced by ADP at different concentrations and the extent of inhibition was measured over time. The figure shows the changes in IPA induced by different concentrations of ADP over the course of the study.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
FDA Label Image

Figure 9 (Figure 9)

Figure 9 (Figure 9)
This document provides information on the impact of ticagrelor tablets on the pharmacokinetics of co-administered drugs. It includes data on various drugs such as simvastatin, atorvastatin, levonorgestrel, ethinyl estradiol, tolbutamide, digoxin, and cyclosporine, and suggests recommendations for dose adjustments or no adjustments when used in combination with ticagrelor at different doses.*
FDA Label Image

Figure3 (Figure3)

Figure3 (Figure3)
FDA Label Image

Figure7 (Figure7)

Figure7 (Figure7)
This is a table summarizing the impact of various intrinsic factors on the pharmacokinetics of the drug ticagrelor. The table shows that factors such as age, gender, ethnicity, renal disease, and hepatic impairment do not require dose adjustments. The mean effects and 90% confidence intervals are given for each factor.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.